Qsymia’s manufacturer also released postmarketing data showing the oral therapy for weight loss was associated with ...

QSYMIA is now approved and available in the United States, South Korea, Sweden, Norway, Poland, Denmark, Iceland, and Finland. The product was recently approved in United Arab Emirates and VIVUS ...

Postmarketing requirement fulfilled based on data demonstrating QYSMIA® reduces blood pressure -CAMPBELL, Calif., Oct. 28, 2024 (GLOBE ...

GoodRx shares rose 1.5% in premarket trading Tuesday after the healthcare company said it will offer a 30-day supply of oral ...

Collaborative telehealth platform will provide patients with immediate access to QSYMIA®, a chronic weight loss medication, enhancing their ...

By making QSYMIA more accessible, GoodRx and Vivus are helping those struggling with weight and obesity find more affordable ways to access the treatments they need. Now, anyone with a valid ...

VIVUS announced today that the U.S. Food and Drug Administration has removed the requirement for a cardiovascular outcome trial for its weight-management medication QSYMIA (phentermine and ...

QSYMIA is now approved and available in the United States, South Korea, Sweden, Norway, Poland, Denmark, Iceland, and Finland. The product was recently approved in United Arab Emirates and VIVUS is ...